UBS Group’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

UBS Group’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,244	Closed	-$777K	–	10253
2023 Q1	$777K	Sell	7,244 -26,610	-79%	-$3.06M	﹤0.01%	4329
2022 Q4	$3.72M	Buy	33,854 +31,951	+1,679%	+$2.07M	﹤0.01%	2778
2022 Q3	$112K	Buy	1,903 +1,359	+250%	+$62.2K	﹤0.01%	5620
2022 Q2	$15K	Sell	544 -30,649	-98%	-$888K	﹤0.01%	7342
2022 Q1	$1.18M	Buy	31,193 +20,284	+186%	+$802K	﹤0.01%	3938
2021 Q4	$431K	Buy	10,909 +10,036	+1,150%	+$314K	﹤0.01%	5101
2021 Q3	$21K	Buy	+873	New	+$20.6K	﹤0.01%	7132
2021 Q2	–	Sell	-776	Closed	-$14K	–	10037
2021 Q1	$14K	Buy	+776	New	+$16K	﹤0.01%	7695

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

UBS Group's RXDX Position: Q2 2023 in Review

UBS Group sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 7,244 shares — an estimated $777K sold.

UBS Group first reported a position in RXDX in Q1 2021 and held it in 8 quarters. The position peaked at $3.72M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

UBS Group reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
UBS Group sold 7,244 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $777K.
UBS Group first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
UBS Group's Prometheus Biosciences, Inc. Common Stock position peaked at $3.72M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.